.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,994,314

« Back to Dashboard

Details for Patent: 5,994,314

Title: Compositions and methods for nucleic acid delivery to the lung
Abstract:A dry powder composition comprises insoluble nucleic acid constructs dispersed within with a hydrophilic excipient material, where the powder particles have an average size in the range from 0.5 .mu.m to 50 .mu.m. Nucleic acid constructs may comprise bare nucleic acid molecules, viral vectors, or vesicle structures. The hydrophilic excipient material will be selected to stabilize the nucleic acid molecules in the constructs, enhance dispersion of the nucleic acid in dry powder aerosols, and enhance wetting of the nucleic acid constructs as they are delivered to moist target locations within the body.
Inventor(s): Eljamal; Mohammed (San Jose, CA), Patton; John S. (San Carlos, CA), Foster; Linda (Sunnyvale, CA), Platz; Robert M. (Half Moon Bay, CA)
Assignee: Inhale Therapeutic Systems, Inc. (San Carlos, CA)
Filing Date:Apr 14, 1995
Application Number:08/422,563
Claims:1. A dry powder nucleic acid composition comprising a cationic lipid-DNA complex dispersed in a hydrophilic excipient.

2. The composition of claim 1, wherein said cationic lipid-DNA complex is dispersed in an excipient selected from the group consisting of mannitol, glycine, and human serum albumin.

3. The composition of claim 2, wherein said cationic lipid is dispersed in one or more of said excipients.

4. The composition of claim 2, wherein said excipient comprises mannitol and human serum albumin.

5. The composition of claim 4, wherein said excipient further comprises glycine.

6. The dry powder nucleic acid composition of claim 1, comprising particles characterized by a mass median aerodynamic diameter (MMAD) from about 0.5 .mu.m to 5 .mu.m.

7. The dry powder nucleic acid composition of claim 1, comprising particles having an average particle size from about 0.5 .mu.m to 5 .mu.m.

8. The dry powder nucleic acid composition of claim 1, wherein DNA present in said cationic lipid-DNA complex comprises a structural region operably linked to a regulatory region.

9. The composition of claim 1, wherein said cationic lipid is either dioleyloxypropyltriethylammonium (DOTMA) or DMRIE.

10. The composition of claim 9, further comprising dioleylphosphatidyl ethanoloamine (DOPE).

11. A dry powder nucleic acid composition comprising viral vector-carried DNA dispersed in a hydrophilic excipient.

12. The dry powder nucleic acid composition of claim 11, wherein said viral vector is an adenovirus vector.

13. The dry powder nucleic acid composition of claim 11, comprising particles characterized by a mass median aerodynamic diameter (MMAD) from about 0.5 .mu.m to 5 .mu.m.

14. The dry powder nucleic acid composition of claim 11, wherein said viral vector-carried DNA comprises a structural region operably linked to a regulatory region.

15. The dry powder composition of claim 11, wherein said excipient is selected from the group consisting of glycine and human serum albumin.

16. The dry powder nucleic acid composition of claim 11, comprising particles characterized by an average particle size from about 0.5 .mu.m to 5 .mu.m.

17. A method for preparing a dry powder nucleic acid composition, comprising:

suspending a cationic lipid-DNA complex in an aqueous solution of an excipient to form a suspension, and

drying the suspension to produce a powder comprising particles of said cationic lipid-DNA complex dispersed within the excipient.

18. The method of claim 17, wherein said drying comprises spraying droplets of said suspension into a gas stream.

19. The method of claim 17, wherein said drying comprises freeze drying.

20. The method of claim 17, wherein said aqueous solution is substantially free from buffer.

21. The method of claim 17, wherein said excipient is selected from the group consisting of mannitol, glycine, and human serum albumin.

22. The method of claim 17, wherein said drying is effective to form particles characterized by a mass median aerodynamic diameter (MMAD) from about 0.5 .mu.m to 5 .mu.m.

23. A method for preparing a dry powder nucleic acid composition, comprising:

suspending viral vector-carried DNA in an aqueous solution of an excipient to form a viral vector in an excipient solution, and

drying said viral vector in said excipient solution to produce a powder comprising particles of said viral vector-carried DNA dispersed within the dried excipient.

24. The method of claim 23, wherein said aqueous solution is buffered.

25. The method of claim 23, wherein said drying comprises spraying droplets of said viral vector-excipient solution into a gas stream.

26. The method of claim 23, wherein said drying is effective to form particles characterized by a mass median aerodynamic diameter (MMAD) from about 0.5 .mu.m to 5 .mu.m.

27. The method of claim 23, wherein said viral vector comprises an adenovirus vector.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc